Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard S Foster

Showing results (31-40 of 115) with videos related to

Pageof 12
Sort By:
Urology|July 8, 2010
Division of prostatic anterior fibromuscular stroma reduces urethral resistance in an ex vivo human prostate modelYaron Ehrlich, Richard S Foster, Richard Bihrle, et al.
Urologic Oncology|May 26, 2020
Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levelsRyan W Speir, Adam C Calaway, Lawrence H Einhorn, et al.
The American Journal of Surgical Pathology|August 19, 2004
Cystic trophoblastic tumor: a nonaggressive lesion in postchemotherapy resections of patients with testicular germ cell tumorsThomas M Ulbright, John D Henley, Oscar W Cummings, et al.
European Urology|August 25, 2019
Reply to Gregory J. Nason, Michael A.S. Jewett, and Robert J. Hamilton's Letter to the Editor re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol 2019;76:607-609: Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular CancerAdam C Calaway, Lawrence H Einhorn, Timothy A Masterson, et al.
The Journal of Urology|April 13, 2004
Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancerAshraf A Mosharafa, Richard S Foster, Michael O Koch, et al.
The Journal of Urology|September 8, 2005
Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors?Stephen D W Beck, Richard S Foster, Richard Bihrle, et al.
Urologic Oncology|September 9, 2010
Serum tumor markers in testicular cancerYaron Ehrlich, Stephen D W Beck, Richard S Foster, et al.
Human Pathology|May 31, 2006
OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapyMing-Tse Sung, Timothy D Jones, Stephen D Beck, et al.
The Journal of Urology|February 14, 2007
Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy?Stephen D W Beck, Liang Cheng, Richard Bihrle, et al.
European Urology|June 9, 2019
Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular CancerAdam C Calaway, Lawrence H Einhorn, Timothy A Masterson, et al.
Pageof 12

Showing results (31-40 of 115) with videos related to

Sort By:
Pageof 12
Urology|July 8, 2010
Division of prostatic anterior fibromuscular stroma reduces urethral resistance in an ex vivo human prostate modelYaron Ehrlich, Richard S Foster, Richard Bihrle, et al.
Urologic Oncology|May 26, 2020
Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levelsRyan W Speir, Adam C Calaway, Lawrence H Einhorn, et al.
The American Journal of Surgical Pathology|August 19, 2004
Cystic trophoblastic tumor: a nonaggressive lesion in postchemotherapy resections of patients with testicular germ cell tumorsThomas M Ulbright, John D Henley, Oscar W Cummings, et al.
European Urology|August 25, 2019
Reply to Gregory J. Nason, Michael A.S. Jewett, and Robert J. Hamilton's Letter to the Editor re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol 2019;76:607-609: Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular CancerAdam C Calaway, Lawrence H Einhorn, Timothy A Masterson, et al.
The Journal of Urology|April 13, 2004
Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancerAshraf A Mosharafa, Richard S Foster, Michael O Koch, et al.
The Journal of Urology|September 8, 2005
Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors?Stephen D W Beck, Richard S Foster, Richard Bihrle, et al.
Urologic Oncology|September 9, 2010
Serum tumor markers in testicular cancerYaron Ehrlich, Stephen D W Beck, Richard S Foster, et al.
Human Pathology|May 31, 2006
OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapyMing-Tse Sung, Timothy D Jones, Stephen D Beck, et al.
The Journal of Urology|February 14, 2007
Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy?Stephen D W Beck, Liang Cheng, Richard Bihrle, et al.
European Urology|June 9, 2019
Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular CancerAdam C Calaway, Lawrence H Einhorn, Timothy A Masterson, et al.
Pageof 12